Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?

Ann Intern Med. 2020 Feb 18;172(4):281-282. doi: 10.7326/M19-3337. Epub 2020 Jan 14.

Abstract

This is the prepublication, author-produced version of a manuscript accepted for publication in Annals of Internal Medicine. This version does not include post-acceptance editing and formatting. The American College of Physicians, the publisher of Annals of Internal Medicine, is not responsible for the content or presentation of the author-produced accepted version of the manuscript or any version that a third party derives from it. Readers who wish to access the definitive published version of this manuscript and any ancillary material related to this manuscript (e.g., correspondence, corrections, editorials, linked articles) should go to Annals.org or to the print issue in which the article appears. Those who cite this manuscript should cite the published version, as it is the official version of record.

MeSH terms

  • Adenine / adverse effects
  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Alanine
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use*
  • Female
  • HIV Infections / prevention & control*
  • Humans
  • Male
  • Pre-Exposure Prophylaxis / methods*
  • Tenofovir / analogs & derivatives
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • Tenofovir
  • tenofovir alafenamide
  • Adenine
  • Alanine